FDA QMSR Transition: The U.S. Agent's Role for Foreign Manufacturers

For foreign medical device manufacturers preparing for the transition from the Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR), the role of a U.S. Agent can extend beyond basic FDA correspondence. While U.S. Agent service fees are not standardized, how can a manufacturer effectively evaluate the cost-benefit of different support models for this specific QMSR transition? Specifically, what key factors typically differentiate a standard representation fee from a more comprehensive QMSR support package? For instance, how does the scope of work—such as performing a gap analysis between the existing QMS and QMSR requirements, assisting in the remediation of procedures, or providing staff training on the incorporation of ISO 13485:2016 principles—influence the fee structure? Furthermore, how might a manufacturer’s own characteristics, including the complexity of its device portfolio (e.g., a single Class II device versus multiple device families) and the maturity of its current quality system, affect the level of effort and associated costs proposed by a U.S. Agent? When evaluating potential partners, what criteria should be used to distinguish between a purely administrative agent and one that provides strategic quality and regulatory guidance throughout the transition, and what considerations are important when defining the service agreement to ensure clear deliverables and expectations are met ahead of the compliance deadline? --- *This Q&A was AI-assisted and reviewed for accuracy by Lo H. Khamis.*